Capital Efficiency In Cardiovascular Outcomes Trials

Cardiovascular outcomes trials (CVOTs) are among the most demanding studies in drug development—large, multi-year, multinational efforts where completion depends on accumulating enough cardiovascular events rather than hitting a fixed calendar date. That structure makes them especially vulnerable to delays, and every added month or coordination gap carries a real financial cost that can slow patient access to new therapies.

New lifecycle modeling from the Tufts Center for the Study of Drug Development examined a large set of Phase III CVOTs to compare traditional, multi-vendor execution against a single, integrated operating model spanning clinical research and manufacturing. The findings showed that integration was consistently linked to meaningfully higher expected program value and strong returns relative to implementation costs, holding up even under more conservative assumptions. These results point to a clear takeaway for teams planning late-stage cardiometabolic programs: closing coordination gaps between clinical execution and supply functions, and proactively managing event accrual, can shorten timelines, protect budgets, and preserve program value. Sponsors evaluating how to structure their next CVOT can use this analysis to weigh the financial tradeoffs of operational alignment before committing capital.